Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.

abstract：BACKGROUND:In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR ...

journal_title：Antiviral therapy

authors： Degasperi E,Valenti L,Aghemo A,De Francesco R,Rumi M,Soffredini R,Donnici L,Cheroni C,Fargion S,Zanoni V,Orsi E,Colombo M

更新日期：2014-01-01 00:00:00

abstract：:The balance of virus production and clearance for untreated patients with chronic hepatitis C virus (HCV) results in a decline of viraemia when initiating active antiviral treatment. During the first phase of interferon-alpha therapy, after a delay of about 8-9 h, the kinetics of the viral load is characterized by a r...

journal_title：Antiviral therapy

authors： Herrmann E,Neumann AU,Schmidt JM,Zeuzem S

更新日期：2000-06-01 00:00:00

abstract：:Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold ...

journal_title：Antiviral therapy

authors： Periard D,Yerly P,Hayoz D,Mazzolai L,Widmeier A,Cavassini M

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3. PATIENTS AND METHODS:Seventy patients with CD4<200 cells/mm3 and CV<1000 copies/ml were enrolled in a 6-month randomized con...

journal_title：Antiviral therapy

authors： Delaugerre C,Gourlain K,Tubiana R,Carcelain G,Marcelin AG,Chouquet C,Mouroux M,Duvivier C,Autran B,Costagliola D,Katlama C,Calvez V

更新日期：2003-06-01 00:00:00

abstract：BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

journal_title：Antiviral therapy

authors： Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...

journal_title：Antiviral therapy

authors： Boettiger DC,Kerr S,Ditangco R,Chaiwarith R,Li PC,Merati TP,Pham TT,Kiertiburanakul S,Kumarasamy N,Vonthanak S,Lee CK,Van Kinh N,Pujari S,Wong WW,Kamarulzaman A,Zhang F,Yunihastuti E,Choi JY,Oka S,Ng OT,Kantipong

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:The aim of the study was to analyse the response to highly active antiretroviral therapy (HAART) initiated at the time of primary HIV infection (PHI) in patients infected with a virus resistant to > or = 1 drug of their treatment compared with patients infected with a wild-type virus. METHODS:We analysed dat...

journal_title：Antiviral therapy

authors： Chaix ML,Desquilbet L,Descamps D,Costagliola D,Deveau C,Galimand J,Goujard C,Signori-Schmuck A,Schneider V,Tamalet C,Pellegrin I,Wirden M,Masquelier B,Brun-Vezinet F,Rouzioux C,Meyer L,French PRIMO Cohort Study Group (ANR

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA ...

journal_title：Antiviral therapy

authors： Huang YW,Takahashi S,Tsuge M,Chen CL,Wang TC,Abe H,Hu JT,Chen DS,Yang SS,Chayama K,Kao JH

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential thera...

journal_title：Antiviral therapy

authors： Flores MV,Corbau RG,Guionaud S

更新日期：2013-01-01 00:00:00

abstract：:Oseltamivir phosphate is an FDA-approved treatment for influenza that has been available for prescription use in the USA since 1999. The present report describes findings from a post-marketing safety study of skin reactions associated with oseltamivir use. All patients in the claims-derived Ingenix Research Database w...

journal_title：Antiviral therapy

authors： Nordstrom BL,Oh K,Sacks ST,L'Italien GJ

更新日期：2004-04-01 00:00:00

abstract：OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

journal_title：Antiviral therapy

authors： Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

更新日期：2006-01-01 00:00:00

abstract：:Active pharmaceutical ingredients (APIs) are the molecular entities that exert the therapeutic effects of medicines. This article provides an overview of the major APIs that are entered into antiretroviral therapy (ART), outlines how APIs are manufactured, and examines the regulatory and cost frameworks of manufacturi...

journal_title：Antiviral therapy

authors： Fortunak JM,de Souza RO,Kulkarni AA,King CL,Ellison T,Miranda LS

更新日期：2014-01-01 00:00:00

abstract：:Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

journal_title：Antiviral therapy

authors： Xie X,Jiang Y,Zeng Y,Liu H

更新日期：2020-06-04 00:00:00

abstract：:The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has ...

journal_title：Antiviral therapy

authors： Marra CM

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

journal_title：Antiviral therapy

authors： Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

更新日期：2018-01-01 00:00:00

abstract：:HBV is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma. As the virus itself is non-cytopathic, it is widely accepted that both viral control and liver pathology are mediated by the host immune system. Until recently, the focus ...

journal_title：Antiviral therapy

authors： Bertoletti A,Maini MK,Ferrari C

更新日期：2010-01-01 00:00:00

abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

journal_title：Antiviral therapy

authors： Calle Serrano B,Manns MP

更新日期：2012-01-01 00:00:00

abstract：:With the advent of the human immunodeficiency virus (HIV) protease inhibitors and the non-nucleoside reverse transcriptase inhibitors, the importance of drug-drug interactions with antiretroviral agents is becoming increasingly recognized. Every clinician involved in the care of HIV-infected persons should have a broa...

journal_title：Antiviral therapy

authors： Burger DM,Hoetelmans RM,Koopmans PP,Meenhorst PL,Mulder JW,Hekster YA,Beijnen JH

更新日期：1997-07-01 00:00:00

abstract：BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse mode...

journal_title：Antiviral therapy

authors： Vermeulen JN,Meijer DK,Over J,Lange J,Proost JH,Bakker HI,Beljaars L,Wit FW,Prins JM

更新日期：2007-01-01 00:00:00

abstract：:Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

journal_title：Antiviral therapy

authors： Llibre JM

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. METHODS:Ontario HIV Treatment Network Cohort Study parti...

journal_title：Antiviral therapy

authors： Gillis J,Smieja M,Cescon A,Rourke SB,Burchell AN,Cooper C,Raboud JM,OHTN Cohort Study Group.

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among adolescents switching from efavirenz (EFV) to RPV are limited. This study investigated the ph...

journal_title：Antiviral therapy

authors： Jantarabenjakul W,Anugulruengkitt S,Kasipong N,Thammajaruk N,Sophonphan J,Bunupuradah T,Cressey TR,Colbers A,Burger DM,Phongsamart W,Puthanakit T,Pancharoen C,HIVNAT 220 study.

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity. METHODS:This was an open-label, randomized, two-treat...

journal_title：Antiviral therapy

authors： Aarnoutse RE,Wasmuth JC,Fätkenheuer G,Schneider K,Schmitz K,de Boo TM,Reiss P,Hekster YA,Burger DM,Rockstroh JK

更新日期：2003-08-01 00:00:00

abstract：:Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

journal_title：Antiviral therapy

authors： Kim BK,Revill PA,Ahn SH

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVES:To evaluate whether fuzzy operators can be usefully applied to the interpretation of genotypic HIV-1 drug resistance by experts, and to improve the prediction of salvage therapy outcome by adapting interpretation rules of genotypic resistance on the basis of their association with virological response data. ...

journal_title：Antiviral therapy

authors： De Luca A,Vendittelli M,Baldini F,Di Giambenedetto S,Trotta MP,Cingolani A,Bacarelli A,Gori C,Perno CF,Antinori A,Ulivi G

更新日期：2004-08-01 00:00:00

abstract：BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...

journal_title：Antiviral therapy

authors： Maimone S,Musolino C,Squadrito G,Raffa G,Pollicino T,Raimondo G

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:HIV type-1 (HIV-1) has been shown to be frequently transmitted by acutely infected patients. We investigated the relationship between the dynamics of HIV-1 transmission within recently infected patients, the HIV-1 variability and the transmission of antiretroviral drug resistance. METHODS:We included patien...

journal_title：Antiviral therapy

authors： Recordon-Pinson P,Anies G,Bruyand M,Neau D,Morlat P,Pellegrin JL,Groppi A,Thiébaut R,Dabis F,Fleury H,Masquelier B,ANRS CO3 Aquitaine Cohort.

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Pegylated interferon/ribavirin combination is currently the standard treatment for chronic hepatitis C virus (HCV) infection. Body weight adjustment of ribavirin is crucial for response. However, previous studies found no relation between ingested dose and plasma concentration. The aim of this study was to d...

journal_title：Antiviral therapy

authors： Maynard M,Pradat P,Gagnieu MC,Souvignet C,Trepo C

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

journal_title：Antiviral therapy

authors： Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:CD4(+) T-cell count recovery after antiretroviral therapy (ART) initiation is associated with improved health outcomes. It is unknown how the CD4(+) T-cell counts of African HIV patients recover following ART initiation. METHODS:We examined CD4(+) T-cell count recovery in a large cohort of HIV-positive pati...

journal_title：Antiviral therapy

authors： Kanters S,Nachega J,Funk A,Mukasa B,Montaner JS,Ford N,Bucher HC,Mills EJ

更新日期：2014-01-01 00:00:00